Can-Fite BioPharma (CANF) Share-based Compensation Growth (5y) (2021 - 2026)
Powered by 
Analysis
Can-Fite BioPharma (CANF) Share-based Compensation Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.30% |
| Dec 31, 2025 | -59.31% |
| Dec 31, 2024 | -56.51% |
| Dec 31, 2023 | 124.78% |
| Dec 31, 2022 | 78.49% |
| Dec 31, 2021 | -80.10% |